1
Home
Companies

Inozyme

Inozyme
Leadership team

Mr. Axel Bolte M.B.A., M.Sc. (Co-Founder, Pres, CEO & Director)

Dr. Demetrios Braddock M.D., Ph.D. (Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer)

Mr. Sanjay S. Subramanian M.B.A., M.S. (CFO & Principal Accounting Officer)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
0 - 50
Headquarters
Boston, Massachusetts, United States
Established
2016
Company Registration
SEC CIK number: 0001693011
Traded as
NASDAQ:INZY
Social Media
URL
https://www.inozyme.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
History

Inozyme was founded in 2014 by two experienced bio-technologies entrepreneurs, Dr. Jeffrey Smith and Dr. Matthew Miller. Inozyme develops therapeutic solutions targeting rare metabolic and bone diseases, driven by an efficient development pipeline and cutting-edge technology platform.

Mission
We are dedicated to developing innovative therapeutic solutions that empower our community of patients and families living with rare metabolic and bone diseases.
Vision
We aspire to be the leader in the development of advanced therapeutic solutions that improve the lives of people in the rare disease community.
Key Team

Dr. Soojin Kim Ph.D. (Sr. VP & Chief Technical Operations Officer)

Dr. Yves Sabbagh Ph.D. (Chairman of Scientific Advisory Board, Sr. VP & Chief Scientific Officer)

Mr. Stefan Riley (Director of Investor Relations)

Ms. Gayle Gironda (Sr. VP & Chief People Officer)

Dr. David Thompson M.A., M.S., Ph.D. (Chief Devel. Officer)

Mr. Stephen J. Di Palma M.B.A, M.B.A. (Consultant)

Dr. Kurt C. Gunter FASCP, M.D., Ph.D. (Chief Medical Officer)

Recognition and Awards
Inozyme has been the recipient of numerous awards and recognitions. These include the 2019 Biotechnology Innovation Organization Emerging Company of the Year, the 2020 Silicon Valley Health Accelator Technology Innovation Award and the 2021 National Institutes of Health Grand Challenges for Human Health Program Runner Up Award.
References

https://in.investing.com/equities/inozyme-pharma-inc

https://finance.yahoo.com/quote/INZY/profile?p=INZY

https://www.crunchbase.com/organization/inozyme

https://www.inozyme.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Inozyme
Leadership team

Mr. Axel Bolte M.B.A., M.Sc. (Co-Founder, Pres, CEO & Director)

Dr. Demetrios Braddock M.D., Ph.D. (Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer)

Mr. Sanjay S. Subramanian M.B.A., M.S. (CFO & Principal Accounting Officer)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
0 - 50
Headquarters
Boston, Massachusetts, United States
Established
2016
Company Registration
SEC CIK number: 0001693011
Traded as
NASDAQ:INZY
Social Media
URL
https://www.inozyme.com